AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Rani Therapeutics Holdings Inc (NASDAQ:RANI)
1.46 USD
-0.070 4.575%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.53 |
|---|---|
| Change | -0.070 4.575% |
| 52 W H/L (in USD) | 8.750/1.820 |
| EBITDA (in USD) | -62.735M |
| PE Ratio | -- |
| Volume | 61791 |
| Diluted Eps TTM | -1.29 |
| Total Assets (in USD) | 57.916M |
|---|---|
| Total Liabilities (in USD) | 32.473M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 6.364M |
| Market Cap (in USD) | 236.187 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 2.717M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
2051 Ringwood Avenue, San Jose, CA, United States, 95131
408 457 3700
Employees: 140
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Mir A. Imran | Exec. Chairman | 1956 |
| 2. | Mr. Talat Imran | CEO & Director | 1981 |
| 3. | Mr. Svai S. Sanford | Chief Financial Officer | 1970 |
| 4. | Dr. Mir Hashim | Chief Scientific Officer | 1960 |
| 5. | Mr. Eric Groen | Gen. Counsel | NA |
| 6. | Ms. Bella Vazquez | VP of HR | NA |
| 7. | Mr. Mir A. Imran | Executive Chairman | 1956 |
| 8. | Mr. Talat Imran | CEO & Director | 1982 |
| 9. | Mr. Eric Groen | General Counsel | 1971 |
| 10. | Ms. Bella Vazquez | Vice President of Human Resources | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.100 1.471% | 76.02 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.290 1.740% | 75.45 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+7.500 1.514% | 493.79 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-8.890 1.289% | 687.43 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -63.274M | -53.047M | -16.668M | -26.587M |
| Minority Interest | -32.756M | 44.757M | - | - |
| Net Income | -63.344M | -53.088M | -16.703M | -26.597M |
| Selling General Administrative | 26.844M | 27.834M | 4.962M | 3.465M |
| Gross Profit | - | 2.717M | 0.462M | 0.979M |
| Reconciled Depreciation | 0.548M | 0.497M | 0.589M | 0.564M |
| Ebit | -63.451M | -51.599M | -16.544M | -27.065M |
| Ebitda | -62.203M | -51.51M | -15.892M | -26.078M |
| Depreciation And Amortization | 1.248M | 0.089M | 0.652M | 0.987M |
| Operating Income | -63.451M | -51.599M | -16.544M | -27.065M |
| Other Operating Expenses | 63.451M | 54.316M | 17.006M | 28.044M |
| Interest Expense | 1.071M | 0.466M | 0.124M | 0.01M |
| Tax Provision | 0.07M | 0.041M | 0.035M | 0M |
| Interest Income | 1.248M | 0.089M | 0.063M | 0.423M |
| Net Interest Income | 0.177M | -0.377M | -0.061M | 0.413M |
| Income Tax Expense | 0.07M | 0.041M | 0.035M | 0.01M |
| Total Revenue | 0M | 2.717M | 0.462M | 0.979M |
| Total Operating Expenses | 63.451M | 54.316M | 17.006M | 28.044M |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 0.177M | -1.448M | -0.124M | 0.478M |
| Net Income From Continuing Ops | -63.344M | -53.088M | -16.703M | -26.587M |
| Net Income Applicable To Common Shares | -61.176M | -8.331M | -16.703M | -26.587M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 57.916M | 108.027M | 124.207M | 79.415M | 23.022M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.308M | 1.942M | 2.142M | 0.167M | 0.158M |
| Total Liab | 32.473M | 34.023M | 2.64M | 192.754M | 119.658M |
| Total Stockholder Equity | 12.866M | 36.855M | 47.411M | -113.339M | -96.636M |
| Other Current Liab | 1.726M | 2.349M | 1.56M | 0.695M | 3.121M |
| Common Stock | 0.005M | 0.005M | 0.005M | 0.664M | 0.664M |
| Capital Stock | 0.005M | 0.005M | 0.005M | 0.664M | 0.664M |
| Retained Earnings | -72.889M | -38.919M | -8.331M | -114.003M | -97.3M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | - | - | - | 1.625M |
| Cash | 6.364M | 27.007M | 117.453M | 73.058M | 16.536M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 7.989M | 4.815M | 2.64M | 5.308M | 3.498M |
| Current Deferred Revenue | - | - | - | 2.717M | 0.179M |
| Net Debt | 23.735M | 3.207M | -117.453M | -69.287M | -16.536M |
| Short Term Debt | 5.615M | 1.006M | - | 1.359M | - |
| Short Long Term Debt | 4.897M | - | - | 1.359M | - |
| Short Long Term Debt Total | 30.099M | 30.214M | - | 3.771M | - |
| Other Stockholder Equity | 85.762M | 75.842M | 55.737M | - | - |
| Property Plant Equipment | - | 6.038M | 4.612M | 4.47M | 4.453M |
| Total Current Assets | 50.547M | 100.924M | 119.595M | 74.945M | 16.944M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 42.675M | 71.475M | - | - | - |
| Net Receivables | 0.2M | - | - | 1.72M | 0.25M |
| Long Term Debt | 24.484M | 29.149M | - | 2.412M | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 0.648M | 1.46M | 1.08M | 0.537M | 0.198M |
| Accumulated Other Comprehensive Income | -0.012M | -0.073M | -124.207M | - | - |
| Non Currrent Assets Other | 0.546M | 1.065M | - | - | 1.625M |
| Non Current Assets Total | 7.369M | 7.103M | 4.612M | 4.47M | 6.078M |
| Capital Lease Obligations | 0.718M | 1.065M | - | - | - |
| Long Term Debt Total | - | 29.149M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -70.817M | -0.506M | -1.2M | -1.532M |
| Total Cashflows From Investing Activities | -72.436M | -0.506M | -1.2M | -1.532M |
| Total Cash From Financing Activities | 29.005M | 77.146M | 72.682M | 0.852M |
| Net Income | -63.344M | -53.088M | -16.703M | -26.587M |
| Change In Cash | -89.946M | 44.395M | 56.522M | -26.947M |
| Begin Period Cash Flow | 117.453M | 73.058M | 16.536M | 43.483M |
| End Period Cash Flow | 27.507M | 117.453M | 73.058M | 16.536M |
| Total Cash From Operating Activities | -46.515M | -32.245M | -14.96M | -26.267M |
| Depreciation | 0.548M | 0.497M | 0.589M | 0.564M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | 0.271M | - | - | - |
| Other Cashflows From Financing Activities | 28.734M | 8.066M | 72.682M | 0.852M |
| Capital Expenditures | 1.619M | 0.506M | 1.2M | 1.581M |
| Change In Working Capital | 0.509M | -3.429M | 1.044M | -0.163M |
| Other Non Cash Items | -0.01M | 0.109M | 0.11M | -0.081M |
| Free Cash Flow | -48.134M | -32.751M | -16.16M | -27.848M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 10 months ago | 518702 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 10 months ago | 148451 |
| 3. | EAM Ultra Micro Cap | 10 months ago | 80767 |
| 4. | Fidelity Extended Market Index | 11 months ago | 73791 |
| 5. | Bridgeway Ultra-Small Company Market | 11 months ago | 51500 |
| 6. | BlackRock Extended Mkt Composite | 1 year ago | 18821 |
| 7. | Fidelity Total Market Index | 11 months ago | 18251 |
| 8. | Fidelity Series Total Market Index | 11 months ago | 16996 |
| 9. | BlackRock Extended Equity Market K | 11 months ago | 16426 |
| 10. | Fidelity Nasdaq Composite Index | 11 months ago | 14915 |
| 11. | NT Ext Equity Mkt Idx Fd - NL | 11 months ago | 14517 |
| 12. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 10 months ago | 14248 |
| 13. | Vanguard Instl Ttl Stck Mkt Idx Tr | 11 months ago | 14248 |
| 14. | NT Ext Equity Mkt Idx Fd - L | 11 months ago | 10721 |
| 15. | Northern Trust Extended Eq Market Idx | 11 months ago | 10721 |
| 16. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1 year ago | 6385 |
| 17. | Spartan Total Market Index Pool E | 11 months ago | 4053 |
| 18. | LUX IM Global Medtech HX | 10 months ago | 3932 |
| 19. | Vanguard U.S. Eq Idx £ Acc | 10 months ago | 3902 |
| 20. | Spartan Extended Market Index Pool E | 11 months ago | 2804 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 11 months ago | 685303 |
| 2. | United Services Automobile Association | 11 months ago | 481300 |
| 3. | Alphabet Inc | 11 months ago | 448492 |
| 4. | Stifel Financial Corp | 11 months ago | 132434 |
| 5. | Bank of America Corp | 1 year ago | 114259 |
| 6. | Geode Capital Management, LLC | 1 year ago | 113629 |
| 7. | BlackRock Inc | 1 year ago | 63583 |
| 8. | Lasry Marc | 1 year ago | 62887 |
| 9. | King Luther Capital Management Corp | 11 months ago | 56129 |
| 10. | Bridgeway Capital Management, LLC | 11 months ago | 51500 |
| 11. | Motco | 1 year ago | 48129 |
| 12. | Renaissance Technologies Corp | 1 year ago | 43700 |
| 13. | Brown Advisory Holdings Inc | 11 months ago | 33911 |
| 14. | State Street Corporation | 1 year ago | 33742 |
| 15. | Lafayette Investments, Inc. | 11 months ago | 19893 |
| 16. | RSM US WEALTH MANAGEMENT LLC | 11 months ago | 19813 |
| 17. | Northern Trust Corp | 1 year ago | 19421 |
| 18. | Prime Capital Investment Advisors, LLC | 1 year ago | 16682 |
| 19. | Activest Wealth Management | 11 months ago | 9800 |
| 20. | Islay Capital Management, LLC | 11 months ago | 9611 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
